Remibrutinib matching placebo

Phase 3

Remibrutinib matching placebo is one of 5 therapeutic programs targeting Chronic Spontaneous Urticaria (CSU). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Chronic Spontaneous Urticaria (CSU)Recruiting

Chronic Spontaneous Urticaria (CSU)Phase 3

Recruiting

Competition

Competitive Landscape

6 competitors in Chronic Spontaneous Urticaria (CSU)

#DrugCompanyPhaseTrials

Rhapsido

Novartis

Phase 3

1 2

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

1 3

Remibrutinib matching placebo

Novartis

Phase 3

1 4

Alpha-0261

AAlphaMol Science Ltd. (Shanghai)

Phase 1

1 5

TLL-018

HHangzhou Highlightll Pharmaceutical Co., Ltd

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Recruiting

Chronic Spontaneous Urticaria (CSU)

NCT06868212

Clinical

Trials by Indication[1]

Chronic Spontaneous Urticaria (CSU)1 trial

A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihistamines

Recruiting· Novartis logo

Novartis·Phase 3·NCT06868212·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Remibrutinib matching placebo. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Remibrutinib matching placebo. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Novartis

Remibrutinib matching placebo

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Chronic Spontaneous Urticaria (CSU)1 trial

References

Drug Info

Quick Facts

Related News